Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,822,128
  • Shares Outstanding, K 2,508,522
  • Annual Sales, $ 43,100 M
  • Annual Income, $ 5,931 M
  • 60-Month Beta 0.65
  • Price/Sales 2.18
  • Price/Cash Flow 8.63
  • Price/Book 3.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.75
  • Number of Estimates 2
  • High Estimate 0.76
  • Low Estimate 0.75
  • Prior Year 0.95
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.09 +2.08%
on 09/24/20
40.13 -5.66%
on 09/09/20
-1.74 (-4.39%)
since 08/28/20
3-Month
37.09 +2.08%
on 09/24/20
42.40 -10.71%
on 08/12/20
-2.69 (-6.63%)
since 06/26/20
52-Week
31.43 +20.46%
on 03/23/20
48.25 -21.53%
on 01/24/20
-4.48 (-10.58%)
since 09/27/19

Most Recent Stories

More News
Smart Inhalers: Global Markets

, /PRNewswire/ -- 

AZN : 54.75 (-1.37%)
GSK : 37.86 (+0.16%)
MHMNF : 54.5000 (unch)
NVS : 87.05 (-0.07%)
[2020-2027] Oncology Drugs Market Size to Reach USD 394.24 Billion by 2027 | Global Market Size, Share, Growth, Trends, Revenue, Sales, Analysis, Report

The global oncology drugs market size is expected to reach USD 394.24 billion by 2027, exhibiting a CAGR of 11.6% during the forecast period.

BAYRY : 15.7800 (+0.57%)
BMY : 59.71 (+0.37%)
LLY : 148.10 (-1.44%)
GSK : 37.86 (+0.16%)
NVS : 87.05 (-0.07%)
PFE : 36.39 (+0.94%)
Glaxo Gets FDA Nod for Nucala for Hypereosinophilic Syndrome

Glaxo's (GSK) Nucala becomes the first and only targeted biologic treatment to be approved for hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.

REGN : 571.92 (-0.37%)
SNY : 51.00 (+0.43%)
AZN : 54.75 (-1.37%)
GSK : 37.86 (+0.16%)
FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and...

GSK : 37.86 (+0.16%)
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK

The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK

JNJ : 147.11 (+1.00%)
SNY : 51.00 (+0.43%)
AZN : 54.75 (-1.37%)
PFE : 36.39 (+0.94%)
GSK : 37.86 (+0.16%)
Pneumococcal Vaccine Market Research Report by Type, by Indication, by Product, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

, /PRNewswire/ --

ALPMF : 15.4900 (+2.45%)
AZN : 54.75 (-1.37%)
CSLLY : 105.5200 (+0.29%)
GSK : 37.86 (+0.16%)
MRK : 82.76 (-0.20%)
PFE : 36.39 (+0.94%)
Anal Fissure Treatment Market reach the valuation of USD 2,526.5 million by the year 2023

Anal Fissure Treatment Market Research Report: by Treatment Type (Medication, Surgery), by Route of Administration (Oral, Topical), by End-user (Hospitals & Clinics, Research & Academic Institutes), and...

ABT : 104.44 (+0.96%)
AGN : 193.02 (+0.02%)
BAYRY : 15.7800 (+0.57%)
ESALF : 90.3500 (+2.67%)
GSK : 37.86 (+0.16%)
VRX.TO : 30.80 (-3.33%)
Anti-Asthmatics And COPD Drugs Global Market Report 2020-30: Covid 19 Implications and Growth

Reportlinker.com announces the release of the report "Anti-Asthmatics And COPD Drugs Global Market Report 2020-30: Covid 19 Implications and Growth" - https://www.reportlinker.com/p05967823/?utm_source=GNW...

GSK : 37.86 (+0.16%)
MRK : 82.76 (-0.20%)
NVS : 87.05 (-0.07%)
Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine

Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.

AZN : 54.75 (-1.37%)
GSK : 37.86 (+0.16%)
TBPH : 15.56 (-1.02%)
VRNA : 6.39 (-0.62%)
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates

J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.

JNJ : 147.11 (+1.00%)
SNY : 51.00 (+0.43%)
AZN : 54.75 (-1.37%)
PFE : 36.39 (+0.94%)
MRK : 82.76 (-0.20%)
LLY : 148.10 (-1.44%)
GSK : 37.86 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 38.32
1st Resistance Point 38.09
Last Price 37.86
1st Support Level 37.70
2nd Support Level 37.55

See More

52-Week High 48.25
Fibonacci 61.8% 41.82
Fibonacci 50% 39.84
Fibonacci 38.2% 37.86
Last Price 37.86
52-Week Low 31.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar